Analysis of Cerebrospinal Fluid Dynamics in Normal Pressure Hydrocephalus

September 15, 2026 updated by: Hee Jin Chang, Chungnam National University Hospital

Analysis of Cerebrospinal Fluid Dynamics in Patients With Normal Pressure Hydrocephalus Using Magnetic Resonance Imaging

This study aims to evaluate whether phase-contrast magnetic resonance imaging (MRI)-based cerebrospinal fluid (CSF) flow dynamics can improve the diagnosis and prognostic assessment of normal pressure hydrocephalus (NPH). In addition, the study investigates how changes in CSF flow parameters before and after CSF diversion procedures are associated with clinical improvement.

Study Overview

Status

Recruiting

Study Type

Interventional

Enrollment (Estimated)

22

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Jung-gu
      • Daejeon, Jung-gu, South Korea, 35015
        • Recruiting
        • Chungnam National University Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients presenting with clinical symptoms consistent with normal pressure hydrocephalus (presence of gait disturbance accompanied by at least one of the following: cognitive impairment or urinary dysfunction)
  • Evans' ratio ≥ 0.3 on brain MRI

Exclusion Criteria:

  • Patients who cannot undergo CSF drainage due to structural abnormalities of the lumbar spine
  • Contraindications to lumbar puncture and CSF drainage (e.g., local infection at the puncture site, suspected elevated intracranial pressure, platelet count < 40,000/µL, or coagulopathy)
  • Coexisting neurological disorders that can also cause gait disturbance, such as Parkinson's disease, atypical parkinsonian syndromes, or vascular parkinsonism
  • Contraindications to MRI (e.g., presence of cardiac pacemakers, implantable defibrillators, or other non-MRI-compatible implantable medical devices)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cerebrospinal fluid drainge

Cerebrospinal fluid drainge

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in Cerebrospinal Fluid Flow Velocity (cm/s) at 30 Minutes Post-Procedure
Time Frame: Baseline (Pre-intervention) and 30 minutes post-intervention

Assessment of cerebrospinal fluid flow parameters before and after the procedure.

Baseline (Pre-intervention) and 30 minutes post-intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in 10-Meter Walk Test (10MWT) Time at 6 Hours and 24 Hours Post-Procedure
Time Frame: Baseline, 6 hours post-procedure, and 24 hours post-procedure

Completion time during the 10-meter walk test, measured in seconds.

Baseline, 6 hours post-procedure, and 24 hours post-procedure
Change from Baseline in 10-Meter Walk Test Step Count at 6 Hours and 24 Hours Post-Procedure
Time Frame: Baseline, 6 hours post-procedure, and 24 hours post-procedure

Number of steps taken during the 10-meter walk test, measured in steps.

Baseline, 6 hours post-procedure, and 24 hours post-procedure
Change from Baseline in Timed Up and Go (TUG) Test Time at 6 Hours and 24 Hours Post-Procedure
Time Frame: Baseline, 6 hours post-procedure, and 24 hours post-procedure

Completion time during the 3-meter TUG test, measured in seconds.

Baseline, 6 hours post-procedure, and 24 hours post-procedure
Change from Baseline in Cognitive Timed Up and Go (Cognitive TUG) Test Time at 6 Hours and 24 Hours Post-Procedure
Time Frame: Baseline, 6 hours post-procedure, and 24 hours post-procedure

Completion time during the 3-meter Cognitive TUG test while performing a dual task, measured in seconds.

Baseline, 6 hours post-procedure, and 24 hours post-procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 11, 2025

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

March 17, 2026

First Submitted That Met QC Criteria

September 15, 2026

First Posted (Actual)

September 21, 2026

Study Record Updates

Last Update Posted (Actual)

September 21, 2026

Last Update Submitted That Met QC Criteria

September 15, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe